Skip to content

The Effect of Desflurane vs Sevoflurane on Perioperative Respiratory Complications in Laryngeal Mask Airway Anesthesia

The Effect of Desflurane vs Sevoflurane on Perioperative Respiratory Complications in Laryngeal Mask Airway Anesthesia: A Prospective Randomized Double-blinded Control Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03006250
Enrollment
220
Registered
2016-12-30
Start date
2016-08-31
Completion date
2019-07-31
Last updated
2018-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia; Adverse Effect, Laryngeal Masks, Respiratory System Abnormalities

Keywords

Desflurane, Sevoflurane, Respiratory Complications

Brief summary

The effects of desflurane versus sevoflurane in adult patients undergoing LMA anesthesia on respiratory events during a less than 2-hour elective surgery.

Detailed description

Laryngeal Mask Airway (LMA) anesthesia is generally performed for ambulatory surgery to avoid the use of neuromuscular blocking agents and to facilitate rapid emergence from anesthesia. Inhaled anesthetics are simply and popularly used during maintenance of anesthesia. The two most recent volatile anesthetic agents, desflurane and sevoflurane, are the two most commonly used in clinical practice for an ambulatory setting. Desflurane is the volatile agent with low blood: gas partition coefficient (0.42). Desflurane's uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications. Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scent. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery. The limitation of desflurane on its odor leads to a controversy if desflurane is similar to or worse than sevoflurane for LMA anesthesia. This is non-inferiority study designed to compare the occurrence of respiratory complications between desflurane and sevoflurane during LMA anesthesia.

Interventions

DRUGDesflurane

Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.

DRUGSevoflurane

Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.

Sponsors

Chiang Mai University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with American Society of Anesthesiologists physical status classification of I-III * Elective surgery * Surgery with expected duration of operation of less than 2 hours * Surgery that anesthesiologist plans to use laryngeal mask airway during anesthesia

Exclusion criteria

* Patients with gastroesophageal reflux disease * Patients with hiatal hernia * Patients with history of upper respiratory tract infection within 1 month before surgery * Heavy smoker (\> 20 cigarettes per day) * Obese patients with body mass index \> 30kg/m2 * Pregnant patients * Unable to provide a written informed consent patients * Surgery requiring non-depolarizing muscle relaxants

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of respiratory complicationsFrom the beginning of operation until 30 minutes after the operationRespiratory complications are coughing, breath holding, laryngospasm, bronchospasm, and desaturation

Secondary

MeasureTime frameDescription
Time of eye openingWithin 30 minutes after the end of operationIt is the time from discontinuation of anesthetic to the eye opening on verbal command.
Time to follow motor commandWithin 30 minutes after the end of operationIt is the time from discontinuation of anesthetic to hand squeezing.
Time of LMA removalWithin 30 minutes after the end of operationIt is the time from discontinuation of anesthetic to removal of LMA.
Changes of blood pressure during anesthesiaEvery 15 minutes, from the beginning of operation until 30 minutes after the operationNon-invasive blood pressure will be recorded at the beginning of anesthesia, every 15 minutes during anesthetic maintenance, and at the time of LMA removal.
Changes of heart rate during anesthesiaEvery 15 minutes, from the beginning of operation until 30 minutes after the operationHeart rate will be recorded at the beginning of anesthesia, every 15 minutes during anesthetic maintenance, and at the time of LMA removal.
Frequency of postoperative nausea and vomiting (PONV)Within 2 hours after operationIt is a number of patients with PONV in the early post-anesthetic period.

Other

MeasureTime frameDescription
Time to achieve a satisfied Modified Aldrete scoreWithin 2 hours after operationIt is the time that the patient is ready to be discharged from post-anesthetic care unit.
Number of Patients with high satisfaction to anesthesiaAt 12-24 hour after surgeryThe satisfaction is graded using a 5-point rating scale.

Countries

Thailand

Contacts

Primary ContactPathomporn Pin-on, M.D.
pinon.pathomporn@gmail.com66-86-897-0009
Backup ContactPrangmalee Leurcharusmee, M.D.
prangmalee.l@cmu.ac.th66-89-759-2647

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026